Stock Ratings / Health Care / BLRX / financials

PHIO (42) GDTC (54) TPST (44) BFRG (40) ⌘ Pro Terminal →

BioLineRx Ltd. (BLRX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.02 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.02

BioLineRx Ltd. (BLRX) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $10.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.02 (-0.01%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLRX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (60/100 Composite)

🔍 WHY BLRX SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 35.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$2.22-9.5% Next Q

Q2 (-2Q)

Grade C+$2.01+1.5% Next Q

Q3 (-1Q)

Grade C+$2.04-1% Next Q

Current

Grade C-$2.02+0.4% Hist 90D α

Trajectory: B- (68) → C- (60)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BLRX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, BLRX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($2.39) or 200D SMA ($2.74) invalidates the momentum regime and cuts Target Base ($2.04) toward Bear Floor ($1.59).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BLRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 60%NO 40%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How BLRX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$281.6K (0% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BLRX)

✓Walkthrough of BLRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BLRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.55%▼ DESCENDING CHANNEL

2026-10-30O $1.95H $2.02L $1.94C $2.02VOL 8.8K

RES: $2.59SUP: $1.78SMA50: $2.39SMA200: $2.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BLRX Butterfly Map → + Track BLRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BLRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BLRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BLRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLRX)

Health Care Rank #207 of 1016 ⚔️ PHIO vs BLRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BLRX vs. PHIO, GDTC, TPST, BFRG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioLineRx Ltd. (BLRX) ranks #207 by composite RQD confidence (60/100, grade C-) and #895 by equity capitalization ($10.1M). Within this direct 5-issuer industry benchmark cohort, BLRX leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BLRX ACTIVE BioLineRx Ltd.	C-	60/100	—	—	—	+1.00%	$10.1M	Benchmark Subject
PHIO Phio Pharmaceuticals Corp.	D-	42/100	—	—	-35.0%	-5.91%	$10.0M	/phio-vs-blrx →
GDTC CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	/gdtc-vs-blrx →
TPST Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	/tpst-vs-blrx →
BFRG Bullfrog AI Holdings Inc.	D-	40/100	—	18.8%	-35.0%	+3.88%	$9.4M	/bfrg-vs-blrx →

2. BLRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BioLineRx Ltd. (BLRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $10.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BLRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioLineRx Ltd. (NASDAQ: BLRX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $2.02 (+1.00% 1D, market cap $10.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BLRX ranks #207 in composite RQD confidence.

How does BLRX compare to PHIO and GDTC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLRX carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PHIO (Phio Pharmaceuticals Corp.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, BLRX leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLRX?

For BioLineRx Ltd. (BLRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #207 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLRX trading relative to its 50-day, 200-day, and 52-week technical levels?

BLRX last traded at $2.02 (+1.00% on volume of 4,149 shares), positioning the stock -15.48% below its 50-day simple moving average ($2.39) and -26.28% below its 200-day simple moving average ($2.74). Across its 52-week range of $1.94 to $3.95, BLRX sits at the 4.0% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.77 to $2.27).

BLRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is BioLineRx Ltd. (BLRX)?

In Trailing 12 Months, BLRX converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $281568 in free cash flow (0% FCF margin).

Direct Sub-Reports: BLRX RQD Cockpit BLRX 12M Forecast BLRX Earnings & Move BLRX Dividends & DRIP BLRX Insiders & 13F BLRX Whale Options BLRX Profit Sankey BLRX News & Why